GENE ONLINE|News &
Opinion
Blog

2023-11-01| Asia-Pacific

Victoria Offers Grants to Accelerate mRNA-Based Therapeutics Research

by Sinead Huang
Share To

With almost 60% of Australia’s pharmaceutical exports coming from Victoria, it represents the state’s highest-value advanced manufactured export, supporting more than 100,000 jobs in the biotech sector. Recently, biotech manufacturing startups and research teams in Victoria have the opportunity to advance their research thanks to the mRNA Victoria Research Acceleration Fund. Minister for Economic Growth Tim Pallas launched the third round of this initiative, announcing substantial funding to support the development of RNA and mRNA-based therapeutics.

Related article: Vaccine Development Has No Limits, the Application Direction of mRNA After the Nobel Prize

Victorian Government Funding for Research Teams

The latest round of the mRNA Victoria Research Acceleration Fund provides $500,000 in grants to aid research teams in their efforts to expedite the translation of research findings. These grants can reach up to $100,000 and are primarily intended for teams engaged in early-stage research.

Victoria has established itself as a leader in mRNA (Messenger RNA) technology, bolstered by the presence of Moderna’s mRNA vaccine manufacturing facility in Clayton, a suburb in Melbourne. This facility, which recently reached a significant construction milestone, is anticipated to produce a remarkable 100 million mRNA vaccine doses annually. Melbourne also serves as the headquarters for Moderna in Australia, New Zealand, Southeast Asia, and Oceania. Additionally, the city is now home to the Moderna Regional Research Centre for Respiratory Medicines and Tropical Diseases.

Building a Bright Future for mRNA Therapeutics

Minister Pallas underscores the significance of mRNA in Victoria’s innovation economy, providing employment opportunities in the present and holding immense potential for the future. The collaboration between industry and researchers is poised to unlock mRNA’s capabilities in advanced manufacturing, potentially leading to groundbreaking vaccines and medicines. 

Approximately $27 million has been invested in 42 research projects by the Victorian Government by far to develop new mRNA treatments and vaccines for diseases such as muscular dystrophy, Alzheimer’s, and hard-to-treat cancers. In addition, the state government has committed $10 million to establish the Monash Centre for Advanced mRNA Medicines Manufacturing and Workforce Training. This dedicated training facility aims to prepare the future workforce in the Asia-Pacific region for mRNA therapeutic development and advanced manufacturing, positioning the state as a global hub for mRNA research. “Victoria’s dedicated and talented medical researchers are changing and saving lives – and we’re proud to back them in their vital work,” said Victoria’s Medical Research Minister Ben Carroll.

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Moderna’s Next Act: How mRNA Platform is Tackling Cancer, RSV, and Rare Diseases
2025-10-29
From Nose to Nerves: World-First Clinical Trial Puts Stem Cells in the Spotlight for Spinal Cord Injury
2025-08-28
Will U.S. ‘s HHS $590 Million Investment Spark a New Era in mRNA Vaccines for Pandemic Flu Threats?
2025-01-22
LATEST
Study Identifies Roles of CD46 and CD55 in Acute Lymphocytic and Myelogenous Leukemia
2026-01-13
Jubilant Biosys Opens New Noida Facility to Double Early Chemistry Scale-Up Capacity
2026-01-13
Researchers Develop Precise DNA Rewriting Method for Mammalian Cells Using Programmable Tools
2026-01-13
Study Finds Limnospira indica Enhances Plant Growth and Alters Rhizosphere and Endosphere Microbial Communities
2026-01-13
Pharmaceutical Companies Urge FDA to Revise Post-Approval Change Rules to Facilitate US Manufacturing
2026-01-13
First-of-Its-Kind AI Drug Discovery Lab: NVIDIA, Eli Lilly Announce $1B Investment at J.P. Morgan Healthcare
2026-01-12
Retired DEA Judge John Mulrooney and Attorney Andrew Hull to Present on Controlled Substances at January 2026 ACI Summit
2026-01-12
EVENT
2026-01-12
J.P. Morgan Healthcare Conference
San Francisco, California
2026-02-09
World Health Expo Dubai
Dubai Exhibition Centre, Dubai
2026-02-17
BIO Asia 2026 (Life Science Partnerships)
Hyderabad, India
2026-02-24
Rare Disease Week on Capitol Hill (Policy and Advocacy)
Capitol Hill, Washington, D.C.
2026-03-09
HIMSS26 (Digital Health & Hospital IT)
Las Vegas, Nevada
Scroll to Top